Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $15.50

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $15.50.

Several research analysts have commented on the company. Needham & Company LLC raised their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays raised their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $9.21 on Monday. The firm’s 50 day simple moving average is $8.01 and its 200-day simple moving average is $7.84. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $9.50. The firm has a market cap of $1.91 billion, a PE ratio of -15.10 and a beta of 1.75.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Counterweight Ventures LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 591.7% in the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after buying an additional 79,884 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in BioCryst Pharmaceuticals by 40.7% during the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after acquiring an additional 86,571 shares during the last quarter. Principal Financial Group Inc. lifted its position in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 375,890 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after purchasing an additional 481,359 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.